AN2 Therapeutics, Inc. (ANTX) Stock Statistics & Valuation Metrics

AN2 Therapeutics, Inc. has a market cap or net worth of $32.59M. The enterprise value is $283.72M.

AN2 Therapeutics, Inc. has 30,175,720 shares outstanding. The number of shares has decreased by -2.65% in one year.

AN2 Therapeutics, Inc.’s return on equity (ROE) is -0.63 and return on invested capital (ROIC) is -66.65%.

The current PE Ratio of AN2 Therapeutics, Inc. is -0.80. AN2 Therapeutics, Inc.’s PEG ratio is 0.00.

In the last 12 months, AN2 Therapeutics, Inc. had revenue of 0.00 and earned -51.32M in profits. Earnings per share was -1.72.

In the last 12 months, operating cash flow was -42.29M and capital expenditures 0.00, giving a free cash flow of -42.29M billion.

AN2 Therapeutics, Inc. pays an annual dividend of $0.656, resulting in a dividend yield of ―

AN2 Therapeutics, Inc. upcoming earnings date is Aug 7, 2025, After Close (Confirmed).

AN2 Therapeutics, Inc. as a current ratio of 8.43, with Debt / Equity ratio of 15.13%

In the past 12 months, AN2 Therapeutics, Inc. has paid 0.00 in taxes.

AN2 Therapeutics, Inc. EV to EBITDA ratio is -0.39, with an EV/FCF ratio of -0.40.

AN2 Therapeutics, Inc. has $67.06M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$67.06M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for AN2 Therapeutics, Inc. is $1.67, which is 11.43% higher than the current price. The consensus rating is Hold